pirfenidone has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armendáriz-Borunda, J; Gutiérrez-Cuevas, J; Monroy-Ramírez, HC; Sandoval-Rodríguez, A; Santos-García, A; Vazquez-Del Mercado, M | 1 |
| Chen, G; Kaneko, S; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Xu, L; Zhuge, F | 1 |
2 other study(ies) available for pirfenidone and Insulin Resistance
| Article | Year |
|---|---|
Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fibrosis; Heart Diseases; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; PPAR alpha; Pyridones; Random Allocation | 2021 |
Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents; Pyridones; RAW 264.7 Cells | 2019 |